PMID- 29922156
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231112
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 9
DP  - 2018
TI  - Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence 
      and Abstinence: Clinical Observations and Treatment Outcomes.
PG  - 529
LID - 10.3389/fphar.2018.00529 [doi]
LID - 529
AB  - Ibogaine may be effective for transitioning opioid and cocaine dependent 
      individuals to sobriety. American and European self-help groups provided public 
      testimonials that ibogaine alleviated drug craving and opioid withdrawal symptoms 
      after only a single dose administration. Preclinical studies in animal models of 
      addiction have provided proof-of-concept evidence in support of these claims. 
      However, the purported therapeutic benefits of ibogaine are based on anecdotal 
      reports from a small series of case reports that used retrospective recruitment 
      procedures. We reviewed clinical results from an open label case series (N = 191) 
      of human volunteers seeking to detoxify from opioids or cocaine with medical 
      monitoring during inpatient treatment. Whole blood was assayed to obtain 
      pharmacokinetic measures to determine the metabolism and clearance of ibogaine. 
      Clinical safety data and adverse events (AEs) were studied in male and female 
      subjects. There were no significant adverse events following administration of 
      ibogaine in a dose range that was shown to be effective for blocking opioid 
      withdrawal symptoms in this study. We used multi-dimensional craving 
      questionnaires during inpatient detoxification to test if ibogaine was effective 
      in diminishing heroin and cocaine cravings. Participants also completed 
      standardized questionnaires about their health and mood before and after ibogaine 
      treatment, and at program discharge. One-month follow-up data were reviewed where 
      available to determine if ibogaine's effects on drug craving would persist 
      outside of an inpatient setting. We report here that ibogaine therapy 
      administered in a safe dose range diminishes opioid withdrawal symptoms and 
      reduces drug cravings. Pharmacological treatments for opioid dependence include 
      detoxification, narcotic antagonists and long-term opioid maintenance therapy. 
      Our results support product development of single oral dose administration of 
      ibogaine for the treatment of opioid withdrawal during medically supervised 
      detoxification to transition drug dependent individuals to abstinence.
FAU - Mash, Deborah C
AU  - Mash DC
AD  - Department of Neurology, Leonard M. Miller School of Medicine, Miami, FL, United 
      States.
AD  - Department of Molecular and Cellular Pharmacology, Leonard M. Miller School of 
      Medicine, Miami, FL, United States.
FAU - Duque, Linda
AU  - Duque L
AD  - Department of Neurology, Leonard M. Miller School of Medicine, Miami, FL, United 
      States.
FAU - Page, Bryan
AU  - Page B
AD  - Department of Anthropology, University of Miami, Coral Gables, FL, United States.
FAU - Allen-Ferdinand, Kathleen
AU  - Allen-Ferdinand K
AD  - General Medical Practice, Basseterre, Saint Kitts and Nevis.
LA  - eng
PT  - Journal Article
DEP - 20180605
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC5996271
OTO - NOTNLM
OT  - craving
OT  - detoxification
OT  - ibogaine
OT  - noribogaine
OT  - opioid dependence
OT  - withdrawal
EDAT- 2018/06/21 06:00
MHDA- 2018/06/21 06:01
PMCR- 2018/06/05
CRDT- 2018/06/21 06:00
PHST- 2017/12/24 00:00 [received]
PHST- 2018/05/02 00:00 [accepted]
PHST- 2018/06/21 06:00 [entrez]
PHST- 2018/06/21 06:00 [pubmed]
PHST- 2018/06/21 06:01 [medline]
PHST- 2018/06/05 00:00 [pmc-release]
AID - 10.3389/fphar.2018.00529 [doi]
PST - epublish
SO  - Front Pharmacol. 2018 Jun 5;9:529. doi: 10.3389/fphar.2018.00529. eCollection 
      2018.